- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Novartis Hires Patrick Horber as President, International
Appointment comes amid resignation of Marie-France Tschudin from company executive committee.
Effective Sept. 15, Marie-France Tschudin, president, innovative medicines international, chief commercial officer, will be leaving Novartis. In her place, the company has added Patrick Horber with the title of president, international. Currently, Horber works as SVP and president, immunology, AbbVie.
A native of Switzerland with an MD from the University of Zurich, Horber will join Novartis with over 20 years of experience in the biopharma field.
"As a Swiss medical doctor, it is a privilege to join Novartis—a pillar of global biomedical innovation and scientific progress,” said Horber, in a company press release. “I look forward to working alongside our teams to reimagine medicine for and with patients around the globe.”
Reference: Novartis appoints Patrick Horber, M.D., President, International as Marie-France Tschudin, President, Innovative Medicines International and Chief Commercial Officer, steps down from the Executive Committee of Novartis. Novartis. September 6, 2023. Accessed September 6, 2023. https://www.novartis.com/news/media-releases/novartis-appoints-patrick-horber-md-president-international-marie-france-tschudin-president-innovative-medicines-international-and-chief-commercial-officer-steps-down-from-executive-committee-novartis
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
